COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:30, il y a 6 mois 14 jours Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease Sanofi Phase 3 Study Dupixent Regeneron Allergic Fungal Rhinosinusitis
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:30, il y a 6 mois 14 jours Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Dupixent de Sanofi et Regeneron approuvé par la FDA aux États-Unis pour traiter la rhinosinusite fongique allergique, offrant un soulagement aux patients de tous âges Traitement Sanofi Dupixent Regeneron Rhinosinusite Fongique Allergique
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:28, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: JTC plc The Vanguard Group, Inc. discloses a 5.07% interest in JTC plc as of 23-Feb-2026, with 8,748,078 relevant securities owned. Includes purchase of 5,440 1p ordinary securities at 12.99 GBP/unit The Vanguard Group Stock Purchase Securities Ownership Interest Disclosure JTC Plc
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:27, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: Beazley plc The Vanguard Group, Inc. discloses a 5.03% stake in Beazley plc. Details of the ownership disclosed according to Code Rule 8.3 Vanguard Group Ownership Disclosure Stake Code Rule 8.3 Beazley Plc
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:26, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: Schroders plc The Vanguard Group, Inc. discloses 2.51% ownership in Schroders plc. Position disclosed on 23 Feb 2026. Details in Form 8.3 The Vanguard Group, Inc. Form 8.3 Schroders Plc Ownership Disclosure Financial Securities
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:26, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: Life Science REIT plc The Vanguard Group, Inc. discloses a 0.94% stake in Life Science REIT plc. Details of securities and derivative transactions provided Vanguard Group Stake Disclosure Securities Transactions Derivative Transactions Life Science REIT Plc
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:25, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc The Vanguard Group, Inc. discloses a 3.60% interest in Spire Healthcare Group plc. Purchase of 1p ordinary shares at 1.99 GBP per unit on 23 Feb 2026 Disclosure Vanguard Group Spire Healthcare Purchase GBP
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:24, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: Just Group plc The Vanguard Group, Inc. discloses 4.92% stake in Just Group plc. Details on ownership, positions, and dealings provided in Form 8.3 submission Form 8.3 Vanguard Group Dealings Ownership Just Group Plc
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:23, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc The Vanguard Group, Inc. discloses a 5.30% interest in LondonMetric Property plc on 23 Feb 2026. Purchased 186,849 securities at 2.13 GBP per unit Securities The Vanguard Group, Inc. LondonMetric Property Plc Disclosure Purchase
COMMUNIQUÉ DE PRESSE publié le 24/02/2026 à 15:23, il y a 6 mois 14 jours Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited The Vanguard Group, Inc. discloses a 5.24% ownership in Picton Property Income Limited, making a purchase of 37,802 securities at 0.87 GBP per unit Vanguard Group Ownership Disclosure Financial Disclosure Securities Purchase Picton Property Income Limited
Publié le 11/09/2026 à 07:00, il y a 4 heures 3 minutes BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Publié le 11/09/2026 à 07:00, il y a 4 heures 3 minutes BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Publié le 10/09/2026 à 19:30, il y a 15 heures 33 minutes Availability of the 2026 Interim Financial Report
Publié le 11/09/2026 à 04:00, il y a 7 heures 3 minutes Torq Announces Debt Settlement and Corporate Update
Publié le 10/09/2026 à 22:25, il y a 12 heures 38 minutes Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Publié le 10/09/2026 à 15:20, il y a 19 heures 43 minutes MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Publié le 10/09/2026 à 15:00, il y a 20 heures 3 minutes All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Publié le 11/09/2026 à 10:15, il y a 48 minutes TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Publié le 11/09/2026 à 09:20, il y a 1 heure 43 minutes Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Publié le 11/09/2026 à 09:05, il y a 1 heure 58 minutes ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Publié le 11/09/2026 à 09:00, il y a 2 heures 3 minutes Homann Holzwerkstoffe publishes its 2026 half-year report